Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group

Giovanni Mauri1,2 · Stella Bernardi3,4 · Andrea Palermo5 · Roberto Cesareo6 · the Italian Minimally-Invasive Treatments of the Thyroid group

Received: 9 December 2021 / Accepted: 30 January 2022 / Published online: 15 March 2022
© The Author(s) 2022, corrected publication 2022

Abstract
Purpose In this paper, the members of the Italian Working Group on Minimally-Invasive Treatments of the Thyroid (MITT group) aim to summarize the most relevant information that could be of help to referring physicians and that should be provided to patients when considering the use of MITT for the treatment of benign thyroid nodules.
Methods An interdisciplinary board of physicians with specific expertise in the management of thyroid nodules was appointed by the Italian MITT Group. A systematic literature search was performed, and an evidence-based approach was used, including also the knowledge and the practical experience of the panelists to develop the paper.
Results The paper provides a list of questions that are frequently asked by patients to operators performing MITT, each with a brief and detailed answer and more relevant literature references to be consulted.
Conclusions This paper summarizes the most relevant information to be provided to patients and general practitioners/referring physicians about the use of MITT for the treatment of benign thyroid nodules.

Keywords Thyroid nodule · Patient · Radiofrequency · Laser · Ethanol · Microwave

Abbreviations
MITT Minimally invasive treatments for the thyroid
EA Ethanol ablation
TA Thermal ablation
RFA Radiofrequency ablation
FNAC Fine needle aspiration citology
HIFU High Intensity focused ultrasound
LA Laser ablation
MWA Microwave ablation
AFTN Autonomously functioning thyroid nodules
US Ultrasound
PM Pacemaker
ICD Implantable cardioverter
RAI Radioactive iodine

Introduction
Thyroid nodules are a very common occurrence in the general population. In most cases, thyroid nodules are benign, however, even if benign, they can grow and determine compressive symptoms or cosmetic concerns,
The use of MITT is indicated for the treatment of benign thyroid nodules that are symptomatic. It may be considered in benign nodules that tend to grow. Also, MITT, particularly TA, can be used in the treatment of autonomously functioning thyroid nodules in selected cases.

MITT are indicated when thyroid nodules become symptomatic and cause local discomfort or cosmetic concerns. They can be taken into account also in nodules that tend to grow, provided that they are cytologically benign.

Thyroid cysts do not need additional exams other than an US before their treatment. In all the other cases, before undergoing any of these procedures, it is important to ascertain what is the nature of the nodule to treat and verify that it is cytologically benign. This is usually performed by fine needle aspiration cytology (FNAC). In case of nodules with US features indicating a low risk of malignancy or autonomously functioning thyroid nodules (AFTN), a single FNAC is considered sufficient before their treatment.
while it should be repeated in all the other cases to confirm that the nodule is cytologically benign [4, 6]. MITT are not indicated to treat nodules that are cytologically suspicious for malignancy or malignant—except for few selected cases of patients unsuitable for surgery or patients with microcarcinomas [16]. MITT can be used to treat autonomously functioning nodules, and -in this case- it is particularly effective for small (<10 ml) nodules.

How to choose a specific MITT technique over another?

The choice of the technique to use is based on nodule characteristics, local technique availability and physician’s expertise. In general, EA is indicated for cystic or predominantly cystic nodules, while the other techniques, particularly RFA and LA, are indicated for predominantly solid or solid nodules.

The specific technique to use depends on nodule US structure. Thyroid nodules can be classified as solid (<10% of fluid component), predominantly solid (11–50% of fluid component), predominantly cystic (51–90% of fluid component), or cystic (>90% of fluid component) [13, 17]. Spongiform nodules are defined as nodules containing multiple small cysts <5 mm interspersed within solid tissue for nearly all the volume. EA is the preferred technique to use in case of cystic or predominantly cystic thyroid nodules, because it has fewer side effects and lower costs as compared to the other techniques [8]. The other techniques, particularly RFA, LA, and MWA are indicated for the treatment of spongiform, predominantly solid, or solid nodules [18, 19].

In case of AFTN, radioactive iodine remains the first choice treatment modality [1, 3]. However, TA can be performed, also in combination with radiiodine (RAI) ablation, and good results on compressive symptoms and thyroid function normalization have been reported in the literature [20].

How is ethanol ablation (EA) of a thyroid cystic nodule performed?

EA consists of the injection of ethanol into a cystic (or a predominantly cystic) nodule, once its liquid content has been aspirated. Usually, ethanol is injected in an amount corresponding to ~50% of the aspirated liquid volume. After EA, a small plaster is applied to the neck, and the patient remains under observation for about 30 min before returning to activity [21, 22].

How is a thermal ablation (TA) of a benign thyroid nodule performed?

TA consists of the ablation of a solid (or predominantly solid) nodule with the application of thermal energy to the nodule.

With LA, RFA and MWA thermal energy is delivered through small devices that are inserted under ultrasound guidance into the thyroid nodule. By contrast, in case of HIFU, ultrasound waves at high energy are focused on the thyroid nodule to treat, with no need to insert any probe/needle into it. All these procedures are performed in an outpatient setting, without the use of general anesthesia. Local anesthesia is generally used for TA, although some authors reported the use of LA or HIFU without local anesthesia. Sometimes, mild sedation can be performed. During the procedure, the patient should lay on the operating table with the neck extended. Under ultrasound guidance the operator injects a small amount of local anesthetic around the thyroid capsule and into the surrounding soft tissues of the neck. Then, according to the technique applied, one or more small devices are inserted under ultrasound guidance into the thyroid nodules, or the HIFU device is applied to the patient neck, and the ablation is started. With RFA and MWA a single device is inserted into the nodule, and moved several times to achieve ablation of the whole nodule (moving-shot technique), while with LA up to 4 very thin laser fibers are inserted simultaneously into the deeper part of the nodule and then withdrawn in order to achieve the complete ablation of the nodule (pull-back technique). With HIFU, no device is inserted into the thyroid nodule, as the energy is delivered directly through the skin. According to the volume of the nodule and the technique used, the ablation can last from few minutes to up to 30 minutes approximately. During the procedure, the patient can speak to the operator, and the ablation can be stopped immediately in case of discomfort or pain. At the end of the procedure, a plaster and an ice pack are applied to the neck of the patient. The patient should remain under observation for a couple of hours before being discharged. In general, patients can return to their usual activities the day after the intervention. In case of very large nodules, or particularly fragile patients, a couple of days of rest is suggested [15, 23].
How should a patient be prepared for the procedure?

The only special precautions that must be taken before the procedure concern patients with voice changes, previous neck surgery, patients on oral anticoagulants or antiplatelet drugs, and patients with pacemakers or implantable-cardioverter defibrillators (in case RFA is performed with monopolar electrodes).

Patients presenting with voice changes should be evaluated further to exclude the presence of a vocal cord palsy prior to the procedure, as if it is contralateral to the nodule of interest, it is a relative or absolute contraindication to TA (depending on its topographic location). Particularly, before the procedure, thyroid and vocal cord function, comorbidities, and contraindications to treatment should be evaluated; laryngoscopy is recommended in patients with hoarseness, previous neck surgery, or with nodules close to critical structures.

Although MITT carry a low risk of major bleeding, oral anticoagulants or antiplatelet drugs can lead to prolonged bleeding or bruising. Before the procedure, it is recommended withholding oral anticoagulants. Patients with a high-intermediate thromboembolic risk require bridging warfarin with low molecular weight heparin, while patients with low thromboembolic risk do not. Given the low risk of major bleeding, anticoagulants can be resumed at maintenance dose on the evening after the procedure (in association with low molecular weight heparin in case of high-intermediate thromboembolic risk) [24]. Low-dose aspirin should not be discontinued before the procedure given the low bleeding risk of MITT. Patients on dual antiplatelet therapy should have the procedure postponed until the duration of the dual therapy is finished [25]. New oral anticoagulants, which include dabigatran, rivaroxaban, apixaban, and edoxaban, should be hold for 24–36 h and can be safely resumed 24 h after the procedure.

RFA performed with monopolar electrodes may cause electromagnetic interferences, as the heat at the tip of the electrode is produced by an alternating electric field, which might interfere with cardiac pacemakers (PM) or implantable-cardioverter defibrillators (ICD) functions. In patients with a cardiac activity that is not PM-dependent, special precautions are not needed [26]. In patients with a cardiac activity that is PM-dependent, the operator should place a magnet over the device and peripheral pulse should be monitored during the procedure. The magnet placed over the cardiac region is considered to be safer than any PM reprogramming, as it allows an immediate restoration of the PM functions after the procedure. Anyway, bipolar RFA electrode can be used to overcome these issues. Only patients with ICD should have their tachyarrhythmia treatment algorithms programmed off before the procedure. In this case, patients should be monitored during the procedure, and straight after RFA, the ICD should be programmed back to its original settings.

What may a patient expect after the procedure?

Patients may briefly experience mild pain in the days following the treatment; which usually extends as far as the jaw and can be relieved by oral painkillers.

Immediately after the procedure, it is recommended to apply an ice pack on the neck with mild pressure, and to keep the patient under observation for a couple of hours. Generally, there is no need of medication after the procedure. A minority of patients (~10%) may experience neck pain [27, 28] with sensation of local heat sometimes radiating to the jaw, ipsilateral dental arch, mandibular angle, or shoulder. In case of persistent neck pain, oral painkillers such as paracetamol are usually sufficient to relieve patients’ symptoms [27]. In addition, it is recommended avoiding strenuous physical exercise, as well as overextending the throat in the first few days after MITT in order to support the healing process. Otherwise, there are no restrictions on patients’ usual daily routine.

What happens to the nodule after MITT?

After MITT (EA or TA) the nodule starts to reduce in size progressively.

With EA, due to the aspiration of the fluid component, the nodule is immediately reduced in size after the treatment, with an immediate improvement of patients’ symptoms. In the following time, the nodule continues to slightly reduce its volume, and generally it achieves a volume reduction of 60 to 80% at 6 months from treatment [8, 21, 22]. The technique efficacy of EA, which is defined as a volume reduction of at least 50% as compared to the initial nodule volume, is generally achieved in as much as 90% of cases. In case of an insufficient volume reduction, or persistence of compressive symptoms, EA can be easily repeated to achieve the desired result.

By contrast to EA, straight after TA the nodule might appear even slightly enlarged due to the oedema occurring after the treatment, and patients might not experience an immediate benefit. It is ~1 week after the procedure, when the nodule starts to shrink, that patients start feeling a relief from their symptoms. Then, the nodule continues to decrease in size, with a parallel symptom improvement, up to its maximum volume reduction, which is usually achieved between 6 and 24 months after the treatment. Final volume reduction usually ranges from 60–80%, and this
result is generally maintained over time [12, 29]. The technique efficacy of TA is generally achieved in as much as 90% of cases. After treatment, a short period follow-up (after 1 to 3 months from the procedure) with neck US, thyroid test function and clinical visit is generally recommended. Afterwards, patients are generally followed at 6 and 12 months, and every year onward.

**Which side effects and complications might occur after MITT?**

The overall likelihood of modest or severe complications is low, and -when occurring- complications are in the vast majority of cases of minor entity. The most common complications and side effects are bruising and mild pain in the neck. The risk of scarring is minimal. In exceptional cases, there may be temporary hoarseness or nodule rupture and infections.

A low rate of side effects and complications has been reported in the literature [27, 30, 31]. Side effects (7–30%) include: pain, bruising, fever, nodule swelling, cough, and vasovagal reactions. Complications (1–3.5%) may be divided into immediate and delayed. Immediate complications include: hoarseness/voice changes, and skin burns. Delayed complications include: bruising, nodule pseudocystic transformation (also known as nodule rupture) with or without fasciitis, and thyroid dysfunction. Hoarseness/voice changes occur in 0.8–2.4% of patients. They can be due to the thermal injury to the laryngeal nerve or to its compression caused by perinodular edema and generally they resolve spontaneously with the administration of corticosteroids. Also cold solution of 5% dextrose may be injected close to the nerve route as a rescue maneuver [32]. The risk of skin burn is extremely low [27, 30, 33]. In order to avoid it, it can be useful to inject cold fluid in the subcutaneous layers in order to create a cushion that will raise the skin and increase the distance from the nodule [34]. Bruising occurs in 0.8–2.5% of patients, and generally it appears within a couple of hours-days after the procedure, disappearing in a few days-weeks [27, 33]. Pseudocystic transformations/nodule rupture occur in 0.3–4.9% of patients. They manifest as a painful sudden swelling a few days after the procedure. In case of fever and persistence of symptoms, patients should be treated with antibiotics and analgesics [30, 33, 35]. A few isolated cases of transient or immunogenic forms of hyperthyroidism have been reported. In the case of hypothyroidism it is unclear whether this represents part of the natural history of an underlying thyroid pathology or if it is a consequence of MITT. Nevertheless, thyroid function should be monitored at the time of the first follow-up or whenever clinical suspicion of dysfunction arises [33, 36].

**Can the nodule regrow after the procedure?**

After MITT, the treated nodule usually shrinks and changes US features, but a small “remnant” nodule remains. Over time, some nodules might regrow. Regrowth is often asymptomatic and does not necessarily require further treatments.

MITT are very effective in reducing thyroid nodule volume. Nodule shrinkage is associated with change of its US features, as it becomes hypoechoic and avascular. A small “remnant” nodule remains after the procedure. Based on the literature, regrowth (which should be defined as a >50% increase as compared to the smallest recorded volume) occurred in as much as one third of patients in a retrospective 5-year analysis [13]. Regrowth is often asymptomatic and does not require further treatments. In case of rapid nodule regrowth, clinicians might consider US-guided FNAC.

**It is possible to perform more than one treatment?**

Thyroid nodules can be treated more than once with MITT.

Thyroid nodules can be treated with MITT multiple times in order to achieve the desired clinical outcome. Baseline volume may be used to predict how many treatments are needed to achieve a satisfactory nodule reduction. In particular, it has been suggested that one session is enough for small nodules, while 2 or 3 sessions may be required for medium or large size nodules [36, 37]. In case of predominantly cystic nodules treated with EA, it is possible that more than one treatment will be necessary over time. However, the decision of performing more than one MITT session should be based on patient’s complaints (symptoms and cosmetic concerns) rather than the amount of nodule volume reduction, and it should be limited to patients with unresolved clinical problems.

**Will the procedure impact on future thyroid surgery?**

The surgical removal of thyroid nodules appears to be minimally impacted by MITT.

After MITT, radioactive iodine and—most importantly—surgery remain both feasible. In one publication on the topic, it has been shown that RFA did not affect subsequent thyroid surgery and/or histological diagnosis [38]. To ensure that surgical removal of thyroid nodules is not impacted by RFA (or MWA), the active tip of the needle should be kept within the nodule throughout the procedure, allowing the operator to undertreat the areas adjacent to the
What are the pros and cons of MITT in comparison to surgery?

MITT are outpatient procedures with good efficacy, minimal recovery time, and few adverse events. They do not require levothyroxine replacement therapy. On the other hand, a small remnant nodule may remain, MITT do not allow for final pathology, and subsequent treatments may be required.

Standard thyroid surgery is invasive, requires general anesthesia, and has some drawbacks. The duration of a procedure is 2 to 3 h, it requires a hospital stay of 1 or 2 days and the recovery time is usually 1 to 2 weeks. Surgery leads to complete removal of the thyroid nodule, which allows for final pathology, and usually there is no need to repeat the procedure. On the other hand, it leaves a neck scar, it often requires the introduction of levothyroxine replacement therapy, and it carries a higher risk of permanent voice damage, bleeding complications and post-operative pain and -in the case of thyroidectomy- also of hypoparathyroidism [36]. MITT are a therapeutic alternative for the treatment of thyroid nodules that can be performed in an outpatient setting with minimal recovery time and few adverse events. MITT are less invasive, they do not require general anesthesia and have a lower risk of complications. The duration of a procedure is 30 minutes to 1 hour, and the recovery time typically is 1 to 2 days. MITT do not leave scars, do not require replacement therapy, and the risk of permanent voice damage is very low. However, a small nodule remains, requiring a follow-up over time and in some cases to repeat the procedure. In addition, MITT do not allow for final pathology as surgery does, with the risk of missing indolent low-risk cancers.

What are the pros and cons of MITT in comparison to radioactive iodine for the treatment of AFTN?

Radioactive iodine therapy is the gold standard for the treatment of autonomously functioning thyroid nodules. MITT can be used in a few selected cases instead of RAI.

Radioactive iodine therapy is one of the first line treatments for AFTN [3, 39]. RAI therapy with I-131 is given to destroy overactive thyroid tissue and treat hyperthyroidism. Patients are asked to follow some radiation precautions after treatment in order to limit radiation exposure to others, particularly to pregnant women and young children. RAI cannot be used in pregnant or breastfeeding women. RAI may take up to several months to have its effect and in some cases the final result is hypothyroidism, which requires hormone replacement therapy. MITT can be used for the treatment of small AFTN [1, 40]. Its advantages include a rapid reduction of nodule volume [41], and no need of hormonal replacement therapy. Also, MITT can be applied in pregnant and breastfeeding women. Its disadvantages include primarily the lower efficacy in thyroid function normalization as compared to RAI [42], as well as a very low risk of adverse events (voice change). As a rule of thumb, MITT should be used as a treatment for AFTN only in selected cases, preferably in small AFTN when RAI is contraindicated (pregnant and breastfeeding women) or refused by patient, or in women with an immediate desire to conceive.

Author contributions G.M., S.B., A.P., and R.C. ideated the paper and prepared the first draft of the paper. All authors commented on initial versions of the paper, and contributed in the draft of the final version of the text. All authors read and approved the final paper.

the Italian Minimally-Invasive Treatments of the Thyroid group

Enrico Papini7, Luigi Solbiati8, Daniele Barbano9, Salvatore Moni10, Maurilio De Andrea11, Laura Fugazzola12,13, Giovanni Gambelunghe14, Roberto Negro15, Stefano Spiezia16, Fulvio Stacul17, Luca Maria Sconfienza18,19, Marco Cavallaro20, Gaetano Achille21, Vito Cantisani22, Luca Cozzaglio23, Anna Crescenzi24, Francesco De Cobelli25, Roberto Garberoglio26, Gioacchino Giugliano26, Luca Persiani27,28, Bruno Raggiunti29, Ettore Seregni30, Dominique Van Doorne28, Andrea Frasoldati30, Chiara Carzaniga31, Celestino Pio Lombardi32, Giampaolo Papi33, Rinaldo Guglielmi34, Franco Orsi35, Rosa Cerrelli36, Chiara Barbieri37, Pierpaolo Trimboli38,39, Dario Monzani40,41.

7Dipartimento di Endocrinologia, Ospedale Regina Apostolorum, Albano Laziale, Italy; 8Humanitas University, Milano, Italy; 9UO Endocrinologia ASL Nordovest Toscana, Toscana, Italy; 10UOC di Endocrinologia, Azienda Ospedaliera Sant’Andrea, Roma, Italy; 11UO Endocrinologia, Ospedale Mauriziano Torino, Torino, Italy; 12Istituto Auxologico Italiano IRCCS, Milano, Italy; 13Università degli Studi di Milano, Milano, Italy; 14Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy; 15 UO Endocrinologia, Ospedale “V. Fazzi”, Lecce, Italy; 16UO Chirurgia Endocrina ed Ecoguidata, Ospedale del Mare, ASL Napoli, Napoli, Italy; 17Azienda Sanitaria Universitaria Integrata Trieste (ASUGI), Trieste, Italy; 18IRCCS Istituto Ortopedico Galeazzi, Milano, Italy; 19Università degli Studi di Milano, Milano, Italy; 20IRCCS Oncolesi “Giovanni Paolo II”, Unità Operativa ORL, Bari, Italy; 21Policlinico Umberto I, Università Sapienza, Roma, Italy; 22Humanitas Clinical and Research Center IRCCS, Rozzano, Italy; 23UOC Anatomia Patologica, Policlinico Universitario Campus Bio-Medico, Roma, Italy; 24UO Endocrinologia, Ospedale San Raffaele, Università Vita e Salute, Milano, Italy; 25Ospedale Città della Salute Torino, Dipartimento Universitario di Endocrinologia e Malattie Metaboliche, Torino, Italy; 26Department of Head and Neck, Istituto Europeo di Oncologia, IRCCS, Milano, Italy; 27UOC Malattie Endocrine e Diabetologia, ASL Teramo, Teramo, Italy; 28Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; 29AME Associazione Medici Endocrinologi, Udine, Italy; 30Department of Endocrinology and Metabolism, Arcispedale Santa Maria Nuova
IRCCS-ASL, Reggio Emilia, Italy; 31Division of Endocrine and Metabolic Diseases, San Luca Hospital, Istituto Auxologico Italiano, Milano, Italy; 32Department of Gastroenterologic, Endocrine-Metabolic and Nephro-Urologic Sciences, Endocrine Surgery Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 33Unit of Endocrinology, Northern Area, Azienda USL Modena, Modena, Italy; 34Endocrinology Department, Sant’ Andrea Hospital, Roma, Italy; 35Division of Radiology interventistica, Istituto e Ttero di Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico IRCCS, Milano, Italy; 36Division of Interventional Radiology, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; 37European Patients’ Academy on Therapeutic Innovation (EUPATI) Trained Patient, Utrecht, The Netherlands; 38Servizio di Endocrinologia e Diabetologia, Ospedale Regionale di Lugano, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland; 39Facoltà di Scienze Biomediche, Università della Svizzera Italiana (USI), Lugano, Switzerland; 40Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milano, Italy; 41Divisione di Psiconcologia, Istituto Europeo di Oncologia, IRCCS, Milano, Italy

**Funding** Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.

**Compliance with ethical standards**

**Conflict of interest** G.M. received speaking fees from RF Medical, ECO, and GE, advisory board for Terumo and Boston Scientific. All other authors declare no competing interests.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. H. Gharib, E. Papini, J.R. Garber, D.S. Duick, R.M. Harrell, L. Hegedus et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules—2016 Update. Endocr. Pract. 22(5), 622–639 (2016)
2. H. Gharib, E. Papini. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinoi. Metab. Clin. North Am. 36(3), 707–735 (2007), vi
3. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016)
4. E. Papini, C.M. Pacella, L.A. Solbiati, G. Achille, D. Barbaro, S. Bernardi et al. Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. Int. J. Hyperth. 36(1), 376–82 (2019)
5. J.Y. Lee, J.H. Baek, E.J. Ha, J.Y. Sung, J.H. Shin, J.H. Kim et al. 2020 Imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean Society of Thyroid Radiology. Korean J. Radiol. 22(5), 840–860 (2021)
6. E. Papini, H. Monpeyssen, A. Frasoldati, L. Hegedus, 2020 European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules. Eur. Thyroid J. 9(4), 172–185 (2020)
7. C.F. Dietrich, T. Muller, J. Bojunga, Y. Dong, G. Mauri, M. Radzina et al. Statement and recommendations on interventional ultrasound as a thyroid diagnostic and treatment procedure. Ultrasound Med. Biol. 44(1), 14–36 (2018)
8. R. Cesareo, R. G. Tabacco, G.A.M. Naciu, A. Crescenzini, S. Bernardi, F. Romanelli et al. Long-term efficacy and safety of percutaneous ethanol injection (PEI) in cystic thyroid nodules: a systematic review and meta-analysis. Clin. Endocrinol (Oxf). 96(2), 97–106 (2022)
9. L. Hegedus, A. Frasoldati, R. Negro, E. Papini, European thyroid association survey on use of minimally invasive techniques for thyroid nodules. Eur. Thyroid J. 9(4), 194–204 (2020)
10. G. Mauri, C.M. Pacella, E. Papini, L.M. Sconﬁenza, L. Solbiati. Proceedings of the first Italian conference on thyroid minimally invasive treatments and foundation of the Italian research group for thyroid minimally invasive procedures. Int. J. Hyperth. 34(5), 603–605 (2018)
11. R. Cesareo, C.M. Pacella, V. Pasqualini, G. Campagna, M. Iozzino, A. Gallo et al. Laser ablation versus radiofrequency ablation for benign non-functioning thyroid nodules: six-month results of a randomized, parallel, open-label, trial (LARA trial). Thyroid 30(6), 847–56 (2020)
12. P. Trimболi, M. Castellana, L.M. Sconﬁenza, C. Virili, L.C. Pescatori, R. Cesareo et al. Efficacy of thermal ablation in benign non-functioning solid thyroid nodule: a systematic review and meta-analysis. Endocrine 67(1), 35–43 (2020)
13. S. Bernardi, F. Giudici, R. Cesareo, G. Antonelli, M. Cavallaro, M. Deandrea et al. Five-year results of radiofrequency and laser ablation of benign thyroid nodules: a multicenter study from the Italian minimally invasive treatments of the thyroid group. Thyroid 30(12), 1759–1770 (2020)
14. R. Cesareo, S. Manfrini, V. Pasqualini, C. Ambroggi, G. Sanson, A. Gallo et al. Laser ablation versus radiofrequency ablation for thyroid nodules: 12-month results of a randomized trial (LARA II Study). J. Clin. Endocrinol. Metab. 106(6), 1692–1701 (2021)
15. C.M. Pacella, G. Mauri, R. Cesareo, V. Paqualini, R. Cianni, P. De Feo et al. A comparison of laser with radiofrequency ablation for the treatment of benign thyroid nodules: a propensity score matching analysis. Int. J. Hyperth. 33(8), 911–919 (2017)
16. R.G. Yoon, J.H. Baek, J.H. Lee, Y.J. Choi, M.J. Hong, D.E. Song et al. Diagnosis of thyroid follicular neoplasm: fine-needle aspiration versus core-needle biopsy. Thyroid 24(11), 1612–1617 (2014)
17. G. Mauri, C.M. Pacella, E. Papini, L. Solbiati, S.N. Goldberg, M. Ahmed et al. Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid 29(5), 611–618 (2019)
18. D. Tumino, G. Grani, M. Di Stefano, M. Di Mauro, M. Scutari, T. Rago et al. Nodular thyroid disease in the Era of precision medicine. Front. Endocrinol. 10, 907 (2019)
19. M. Andrioli, R. Valcavi, The peculiar ultrasonographic and elastographic features of thyroid nodules after treatment with laser or radiofrequency: similarities and differences. Endocrinol. 47(3), 967–968 (2014)

20. M. Chianelli, V. Bizzarri, V. Todino, I. Misischi, A. Bianchini, F. Graziano et al. Laser ablation and 131-iodine: a 24-month pilot study of combined treatment for large toxic nodular goiter. J. Clin. Endocrinol. Metab. 99(7), E1283–E1286 (2014)

21. J.H. Baek, E.J. Ha, J.Y. Choi, J.Y. Sung, J.K. Kim, Y.K. Shong, Radiofrequency versus ethanol ablation for treating predominantly cystic thyroid nodules: a randomized clinical trial. Korean J. Radiol. 16(6), 1332–1340 (2015)

22. C.C. Yang, Y. Hsu, J.Y. Liou, Efficacy of ethanol ablation for benign thyroid cysts and predominantly cystic nodules: a systematic review and meta-analysis. Endocrinol. Metab. 36(1), 81–95 (2021)

23. G. Mauri, N. Gennaro, M.K. Lee, J.H. Baek. Laser and radiofrequency ablations for benign and malignant thyroid tumors. Int. J. Hyperth. 36(2), 13–20 (2019)

24. A.C. Spyropoulos, J.D. Douketis, How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120(15), 2954–2962 (2012)

25. J. Thachil, A. Gatt, V. Martlew, Management of surgical patients receiving anticoagulation and antiplatelet agents. Br. J. Surg. 95(12), 1437–1448 (2008)

26. S. Bernardi, F. Stacul, M. Zecchin, C. Dobrinja, F. Zanconati, B. Fabris, Radiofrequency ablation for benign thyroid nodules. J. Endocrinol. Investig. 39(9), 1003–1013 (2016)

27. C.M. Pacella, G. Mauri, G. Achille, D. Barbaro, G. Bizzarri, P. De Feo et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules: a multicenter study on 1531 patients. J. Clin. Endocrinol. Metab. 100(10), 3903–3910 (2015)

28. M. Deandrea, F. Garino, M. Alberto, R. Garberoglio, R. Rossetto, N. Bonelli et al. Radiofrequency ablation for benign thyroid nodules according to different ultrasound features: an Italian multicentre prospective study. Eur. J. Endocrinol. 180(1), 79–87 (2019)

29. A.P. Mainini, C. Monaco, L.C. Pescatori, C. De Angelis, F. Sardanelli, L.M. Sconfienza et al. Image-guided thermal ablation of benign thyroid nodules. J. Ultrasound 20(1), 11–22 (2017)

30. J.H. Baek, J.H. Lee, J.Y. Sung, J.I. Bae, K.T. Kim, J. Sim et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology 262(1), 335–342 (2012)

31. C. Kim, J.H. Lee, Y.J. Choi, W.B. Kim, T.Y. Sung, J.H. Baek, Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers. Eur. Radiol. 27(8), 3128–31 (2017)

32. S.R. Chung, J.H. Baek, J.Y. Choi, J.H. Lee, Management strategy for nerve damage during radiofrequency ablation of thyroid nodules. Int. J. Hyperth. 36(1), 204–210 (2019)

33. R. Valcavi, F. Riganti, A. Bertani, D. Formisano, C.M. Pacella, Percutaneous laser ablation of cold benign thyroid nodules: a 3-year follow-up study in 122 patients. Thyroid 20(11), 1253–1261 (2010)

34. S. Bernardi, V. Lanzilotti, G. Papa, N. Panizzo, C. Dobrinja, B. Fabris et al. Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule. Thyroid 26(1), 183–184 (2016)

35. S.R. Chung, J.H. Baek, J.Y. Sung, J.H. Ryu, S.L. Jung, Revisiting rupture of benign thyroid nodules after radiofrequency ablation: various types and imaging features. Endocrinol. Metab. 34(4), 415–421 (2019)

36. S. Bernardi, C. Dobrinja, B. Fabris, G. Bazzocchi, N. Sabato, V. Ulcigrai et al. Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. Int J. Endocrinol. 2014, 934595 (2014)

37. H.K. Lim, J.H. Lee, E.J. Ha, J.Y. Sung, J.K. Kim, J.H. Baek, Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur. Radiol. 23(4), 1044–1049 (2013)

38. C. Dobrinja, S. Bernardi, B. Fabris, R. Eramo, P. Makovac, G. Bazzocchi et al. Surgical and pathological changes after radiofrequency ablation of thyroid nodules. Int J. Endocrinol. 2015, 576576 (2015)

39. R. Cesareo, A. Palermo, V. Pasqualini, S. Manfrini, P. Trimboli, F. Stacul et al. Radiofrequency ablation on autonomously functioning thyroid nodules: a critical appraisal and review of the literature. Front. Endocrinol. 11, 317 (2020)

40. R. Cesareo, A. Palermo, D. Benvenuto, E. Celli, V. Pasqualini, S. Bernardi et al. Efficacy of radiofrequency ablation in autonomous functioning thyroid nodules. A systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 20(1), 37–44 (2019)

41. R. Cervelli, S. Mazzeo, G. Boni, A. Bocciuzzo, F. Bianchi, F. Brozzi et al. Comparison between radioiodine therapy and single-session radiofrequency ablation of autonomously functioning thyroid nodules: a retrospective study. Clin. Endocrinol. 90(4), 608–16 (2019)

42. L. Giovanella, A. Piccardo, C. Pezzoli, F. Bini, R. Ricci, T. Ruberto et al. Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules. Clin. Endocrinol. 89(2), 219–25 (2018)